Literature DB >> 12139658

Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999.

F Bonnet1, P Morlat, G Chêne, P Mercié, D Neau, I Chossat, M Decoin, F Djossou, J Beylot, F Dabis.   

Abstract

OBJECTIVES: To describe the causes of death in HIV-infected patients in the era of highly active antiretroviral therapy (HAART).
METHOD: A retrospective survey conducted in Bordeaux, France. Medical records of all deaths that had occurred in 1998 and 1999 amongst patients followed within the Aquitaine cohort were reviewed by the same physician. Immediate and underlying causes of death were described, taking into account the morbidity at the time of death.
RESULTS: Sixty-six deaths occurred in 1998, and 41 in 1999. Sixty-seven per cent of deceased patients were male. Median age at time of death was 43 years (range 25-71), median CD4 was 162 cells/microL (0-957); 28% of patients had a CD4 count > 200 cells/microL and 7% plasma viral load < 500 HIV-RNA copies/mL. Amongst morbidity present at the time of death, there were 23 bacterial infections, 16 non-Hodgkin's lymphomas, 16 cirrhoses, 15 non HIV-related malignancies, 13 central nervous system diseases and 10 myocardiopathies. The main immediate causes of death were: multiple organ failure (21%), coma (18%), septic shock (15%) and acute respiratory failure (14%). Underlying causes of death were AIDS-defining events (48%), non AIDS HIV-related infection (3%), hepatitis B- or C-associated cirrhosis (14%), non HIV-related malignancies (11%), cardiovascular events (10%), suicide and overdose (6%), treatment-related fatalities (4%), injury (2%) and unknown (2%). Patients dying from AIDS-related events were more often female, had a lower CD4 count, a higher level of HIV-RNA, a shorter history of HIV infection and were less often coinfected with hepatitis B and C viruses than those dying from other underlying causes.
CONCLUSIONS: AIDS-related events are no longer the major causes of death of HIV-infected patients in the era of HAART. This evolving mortality pattern justifies an adaptation of both the epidemiological surveillance and the clinical monitoring of HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12139658     DOI: 10.1046/j.1468-1293.2002.00117.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  21 in total

1.  Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects.

Authors:  B M Bergersen; L Sandvik; J N Bruun; S Tonstad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-28       Impact factor: 3.267

2.  Highly active antiretroviral therapy.

Authors:  Filip Moerman; Alfons Van Gompel; Jan Nimmegeers; Johan Moerman
Journal:  BMJ       Date:  2005-06-11

Review 3.  Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis.

Authors:  Melanie Walker; James G Kublin; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2005-11-23       Impact factor: 9.079

Review 4.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Mortality among HIV-Infected Patients in Resource Limited Settings: A Case Controlled Analysis of Inpatients at a Community Care Center.

Authors:  Nirmala Rajagopalan; Joyce B Suchitra; Anita Shet; Zafar K Khan; Julio Martin-Garcia; Michael R Nonnemacher; Jeffrey M Jacobson; Brian Wigdahl
Journal:  Am J Infect Dis       Date:  2009

6.  Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.

Authors:  Benoît Marin; Rodolphe Thiébaut; Heiner C Bucher; Virginie Rondeau; Dominique Costagliola; Maria Dorrucci; Osamah Hamouda; Maria Prins; Sarah Walker; Kholoud Porter; Caroline Sabin; Geneviève Chêne
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

7.  Causes of Death in Hospitalized HIV Patients in the Early Anti-Retroviral Therapy Era.

Authors:  M Lartey; A Asante-Quashie; A Essel; E Kenu; V Ganu; A Neequaye
Journal:  Ghana Med J       Date:  2015-03

8.  Effects of human immunodeficiency virus encephalitis and drug abuse on the B lymphocyte population of the brain.

Authors:  Iain C Anthony; Dorothy H Crawford; Jeanne E Bell
Journal:  J Neurovirol       Date:  2004-06       Impact factor: 2.643

9.  Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression.

Authors:  Ting-Yi Chen; Eric L Ding; George R Seage Iii; Arthur Y Kim
Journal:  Clin Infect Dis       Date:  2009-11-15       Impact factor: 9.079

10.  Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care.

Authors:  Diana C Lemly; Bryan E Shepherd; Todd Hulgan; Peter Rebeiro; Samuel Stinnette; Robert B Blackwell; Sally Bebawy; Asghar Kheshti; Timothy R Sterling; Stephen P Raffanti
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.